Brand Name | Status | Last Update |
---|---|---|
kaletra | New Drug Application | 2023-07-06 |
lopinavir and ritonavir | ANDA | 2023-10-20 |
lopinavir-ritonavir | ANDA | 2020-11-18 |
norvir | New Drug Application | 2024-07-03 |
paxlovid | New Drug Application | 2025-04-15 |
ritonavir | ANDA | 2024-11-11 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Dasabuvir Sodium / Ombitasvir / Paritaprevir / Ritonavir, Viekira Xr, Abbvie | |||
9333204 | 2035-01-02 | DP | U-1889 |
9744170 | 2035-01-02 | DP | U-1889 |
10105365 | 2035-01-02 | DP | U-1889 |
10201541 | 2032-05-17 | DP | |
10201584 | 2032-05-17 | U-1889 | |
Dasabuvir Sodium / Ombitasvir / Paritaprevir / Ritonavir, Viekira Pak (Copackaged), Abbvie | |||
9629841 | 2033-10-18 | DP | U-1753 |
10201542 | 2033-10-18 | DP | U-1753 |
8466159 | 2032-09-04 | U-1637 | |
8492386 | 2032-09-04 | U-1840 | |
8680106 | 2032-09-04 | U-1637 | |
8685984 | 2032-09-04 | U-1840 | |
8691938 | 2032-04-13 | DS, DP | |
8686026 | 2031-06-09 | DP | |
8420596 | 2031-04-10 | DS, DP | |
9044480 | 2031-04-10 | U-1638 | |
9006387 | 2030-06-10 | U-1687 | |
8642538 | 2029-09-10 | DS, DP | U-1638 |
8188104 | 2029-05-17 | DS, DP | U-1636 |
8501238 | 2028-12-19 | DS, DP | U-1636 |
9139536 | 2028-11-09 | U-1753 | |
8268349 | 2024-08-25 | DP | |
8399015 | 2024-08-25 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis c | D006526 | — | B19.2 | 1 | 9 | 28 | 6 | 19 | 61 |
Hepatitis | D006505 | — | K75.9 | — | 9 | 28 | 3 | 19 | 57 |
Hepatitis a | D006506 | EFO_0007305 | B15 | — | 9 | 28 | 3 | 19 | 57 |
Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 9 | 25 | 6 | 17 | 55 |
Infections | D007239 | EFO_0000544 | — | — | 6 | 18 | 1 | — | 23 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | 1 | 2 | 2 | 5 |
Coinfection | D060085 | — | — | — | 1 | 1 | 1 | — | 2 |
Hepatitis viruses | D006518 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic hepatitis | D006521 | — | K73.9 | — | 9 | 23 | — | 15 | 45 |
Communicable diseases | D003141 | — | — | — | 6 | 11 | — | — | 15 |
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | 5 | 8 | — | — | 12 |
Hepacivirus | D016174 | — | — | — | 2 | 7 | — | 1 | 10 |
Fibrosis | D005355 | — | — | — | 2 | 7 | — | 1 | 9 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 2 | 5 | — | 1 | 7 |
Virus diseases | D014777 | — | B34 | — | 2 | 5 | — | — | 6 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 3 | — | — | 3 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | 1 | — | 1 | 2 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | Ritonavir |
INN | ritonavir |
Description | Ritonavir is an L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver. It has a role as an antiviral drug, a HIV protease inhibitor, an environmental contaminant and a xenobiotic. It is a member of 1,3-thiazoles, a L-valine derivative, a carbamate ester, a member of ureas and a carboxamide. |
Classification | Small molecule |
Drug class | antivirals: HIV protease inhibitors (saquinavir type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1 |
PDB | — |
CAS-ID | 155213-67-5 |
RxCUI | — |
ChEMBL ID | CHEMBL163 |
ChEBI ID | 45409 |
PubChem CID | 392622 |
DrugBank | DB00503 |
UNII ID | O3J8G9O825 (ChemIDplus, GSRS) |